Accelerated Immunosenescence and Chronic Kidney Disease (IRIS)

Centre Hospitalier Universitaire de Besancon

Status: Completed

Conditions: Renal Failure

Treatments: Biological: Blood sample

Study type: Interventional

Funder types: Other

Identifiers

NCT02116270

IRIS API/2012/28

Details and patient eligibility

About

The aim of this study is to investigate the impact of renal function and dialysis techniques on the percentage of senescent T lymphocytes.

Full description

The immunosenescence is a complex and profound remodeling of the immune system during life. It is mainly due to thymic involution and repeated antigenic stimulation. Kidney disease is associated with a decrease in adaptive immunity as evidenced by the decrease in vaccine response and increased susceptibility to infections, similar to those observed in the elderly population.

However, data on aging of the immune system in chronic kidney disease remains incomplete. Furthermore, the determinants of immunosenescence are not also not known. It is possible that "uremic" factors help explain the phenotypic and functional changes of lymphocytes, as antigenic stimuli associated with repeated bio-compatible materials used in dialysis contact.

The purpose of this study is to describe the phenotypes of the immune system of renal and analyze the determinants of these changes.

Enrollment: 222 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient able to understand the reason of the study
• Patient not opposed to the conservation of biological samples for scientific research

Exclusion criteria

• Patient suffering from psychotic illness
• Any history of immunosuppressive therapy (except steroids up to 5mg/day)
• History of cancer (except skin cancer) or treated hematological malignancy
• Infectious episode required hospitalization not older 3 months
• Hepatitis B or C infection
• HIV infection, active or inactive
• For dialysis patients: renal failure on dialysis for less than 3 months and/or have benefited from two techniques for renal replacement therapy in the last 6 months

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

222 participants in 4 patient groups

Control group

Other group

Description:

Patients in this group control (normal renal function) are followed in the urology department. A blood sample is performed on the day of inclusion.

Treatment:

Biological: Blood sample

Severe renal failure

Experimental group

Description:

Patients in this group suffer from renal failure stage 4 and are not under dialysis. A blood sample is performed on the day of inclusion.

Treatment:

Biological: Blood sample

Peritoneal dialysis

Experimental group

Description:

Patients with renal failure, under peritoneal dialysis for at least 3 months. A blood sample is performed on the day of inclusion.

Treatment:

Biological: Blood sample

Hemodialysis

Experimental group

Description:

Patient with renal failure, under hemodialysis for at least 3 months. A blood sample is performed on the day of inclusion.

Treatment:

Biological: Blood sample